Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, noviembre 03
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Insmed Inc
INSM
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$105.80
-3.51
-3.21%
Últ. Act.: Nov 3, 11:19 AM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Ganancias:
Los beneficios de Q3 2026 se publicaron el jue oct 29th, antes de la apertura del mercado
Conferencia telefónica:
La conferencia telefónica más reciente comenzó a las 8:00 a. m., hace 5 días
Haz clic para ver el webcast
Insmed Financials
Insmed (INSM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today
Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
Piero Cingari
PRO
Insmed Q3 EPS $(0.46) Misses $(0.43) Estimate, Sales $524.428M Beat $501.350M Estimate
Insmed (NASDAQ:INSM) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.43) by 6.98 percent. This is a 73.71 percent increase over losses of $(1.75) per share from the same
Benzinga Newsdesk
PRO
Insmed Raises FY2026 Sales Guidance from $1.700B-$1.870B to $1.810B-$1.870B vs $1.801B Est
Insmed (NASDAQ:INSM) raises FY2026 sales outlook from $1.700 billion-$1.870 billion to $1.810 billion-$1.870 billion vs $1.801 billion estimate.
Benzinga Newsdesk
Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed
Insmed shares slip after CFO Sara Bonstein steps down, reaffirms 2026 financial targets.
Vandana Singh
PRO
Insmed Reaffirms FY26 Revenue Guidance Of $1.25B-$1.40B For BRINSUPRI And $450M- $470M For ARIKAYCE
Reaffirms Full-Year 2026 GuidanceAs Insmed continues to build on its operational excellence and momentum, the Company reaffirms its full-year 2026 financial guidance of revenue in the range of $1.25 billion to $1.40
Benzinga Newsdesk
PRO
Insmed Q2 EPS $(0.06) Beats $(0.73) Estimate, Sales $425.486M Beat $392.836M Estimate
Insmed (NASDAQ:INSM) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.73) by 91.78 percent. This is a 96.47 percent increase over losses of $(1.70) per share from the same
Benzinga Newsdesk
